CoChat

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial

Abstract

BACKGROUND Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome. We aimed to investigate the efficacy and safety of levoketoconazole in patients with endogenous Cushing's syndrome. METHODS SONICS is a phase 3, multicentre, open-label, non-randomised, single-arm study in which we recruited adults (≥18 years) with confirmed Cushing's syndrome and a mean 24-h urinary free cortisol (mUFC) of at least 1·5 times the upper limit of normal from 60 hospital and community sites in 19 countries (15 countries in Europe, and Canada, Israel, Turkey, and the USA). Patients were treated with oral levoketoconazole in a 2-21 week incremental dose-titration phase starting at 150 mg twice daily (150 mg increments until mUFC normalisation, maximum 600 mg twice daily) and a 6-month maintenance phase. The primary outcome was the proportion of patients with mUFC normalisation at end of maintenance, without dose increase during the maintenance phase (in the intention-to-treat population). Prespecified adverse events of special interest were potential liver toxicity, corrected QT prolongation, and adrenal insufficiency. This trial is registered with ClinicalTrials.gov, NCT01838551. FINDINGS Between July 30, 2014, and June 30, 2017, 201 individuals were screened and 94 patients were enrolled and received at least one dose of study medication. Of the 94 patients, 80…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30313-4

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Auchus, 2018, 2S,4R-ketoconazole is the relevant enantiomer of ketoconazole for cortisol synthesis inhibition: steroidogenic P450s inhibition involves multiple mechanisms, Endocr Rev, 39

Cited by

See all 101

Metadata

Authors
Fleseriu, M., Pivonello, R., Elenkova, A., Salvatori, R., Auchus, R. J., Feelders, R. A., Geer, E. B., Greenman, Y., Witek, P., Cohen, F., & Biller, B. M. K.
Affiliations
  • Oregon Health & Science University (US)
  • University of Naples Federico II (IT)
  • Medical University of Sofia (BG)
  • Johns Hopkins University (US)
  • University of Michigan (US)
  • Erasmus MC (NL)
  • Memorial Sloan Kettering Cancer Center (US)
  • Tel Aviv University (IL)
  • Massachusetts General Hospital (US)
Corresponding author
Fleseriu, Maria
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2019-11
Volume
7
Issue
11
Pages
855-865
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2974345616
Cited by
101
References
30
Citations by year
2026: 8 · 2025: 14 · 2024: 17 · 2023: 12 · 2022: 22 · 2021: 16 · 2020: 10 · 2019: 2
FWCI
10.15
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Keywords
endogenous Cushing's syndrome, pituitary Cushing's disease, 24-hour urinary free cortisol, dose titration, adrenal insufficiency, hepatotoxicity, QT prolongation, adverse events, treatment efficacy, maintenance therapy, dose-limiting toxicity
MeSH terms
Adolescent, Adrenal Insufficiency, Adult, Aged, Alanine Transaminase, Cushing Syndrome, Female, Humans, Hydrocortisone, Ketoconazole, Long QT Syndrome, Male, Middle Aged, Treatment Outcome, Young Adult, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30313-4
The paper
Fleseriu, M., Pivonello, R., Elenkova, A., Salvatori, R., Auchus, R. J., Feelders, R. A., Geer, E. B., Greenman, Y., Witek, P., Cohen, F., & Biller, B. M. K. (2019). Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30313-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.